Abstract
The complex interaction between the immune system, the tumor and the microenvironment in pancreatic ductal adenocarcinoma (PDA) leads to the resistance of PDA to immunotherapy. To overcome this resistance, combination immunotherapy is being proposed. However, rational combinations that target multiple aspects of the complex anti-tumor immune response are warranted. Novel clinical trials will investigate and optimize the combination immunotherapy for PDA.
| Original language | English (US) |
|---|---|
| Article number | 31 |
| Journal | Chinese Clinical Oncology |
| Volume | 6 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jun 1 2017 |
| Externally published | Yes |
Keywords
- Checkpoint inhibitors
- Combination immunotherapy
- GVAX
- Immunotherapy
- Pancreatic cancer
- Vaccine therapy
ASJC Scopus subject areas
- Oncology
Fingerprint
Dive into the research topics of 'Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS